These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
    Author: Piotrowski J, Yamaki K, Morita M, Slomiany A, Slomiany BL.
    Journal: Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724.
    Abstract:
    The mechanism of gastric mucosal protection by ebrotidine against ethanol-induced mucosal injury was investigated in rats treated intragastrically either with the drug or vehicle. Results of macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30% increase in mucus gel dimension, and showed 20% increase in phospholipids, and the content of sulfo- (18%) and sialomucins (21%). This was accompanied by 1.4-fold increase in mucus gel viscosity, 16% increase in H+ retardation capacity, and 65% increase in hydrophobicity. Our data show that ebrotidine is a unique H2-antagonist capable of enhancement of the physicochemical characteristics of gastric mucus.
    [Abstract] [Full Text] [Related] [New Search]